How much does it cost to build a commercial GMP biologics manufacturing facility?

Capital cost estimates for commercial-scale GMP biologics manufacturing facilities range from approximately $200 million for a modestly sized drug substance facility to over $400 million for large-scale commercial mAb manufacturing infrastructure, and substantially more for specialized modalities requiring contained suites for cytotoxic handling or dedicated viral vector production areas. These figures cover construction and equipment but exclude quality system implementation, personnel hiring and training, and process validation costs that are typically additional.

What is the break-even batch frequency where internal manufacturing becomes more economic than a CDMO?

The break-even batch frequency depends on the specific facility configuration, CDMO pricing, and product volume, but as a directional benchmark, commercial biologic programs producing fewer than four to six batches per year typically find CDMO outsourcing more economical than internal manufacturing when the full fixed cost of an internal facility is accounted for. Above that threshold, internal manufacturing often becomes cost-competitive. For specialized modalities like viral vectors where CDMO per-batch fees are substantially higher than standard mAb CDMOs, the break-even frequency may be lower despite higher internal facility costs.

What is the timeline from a build decision to first commercial GMP batch?

For a greenfield GMP facility, the timeline from build decision to first commercial GMP batch is typically 3 to 5 years: 12 to 18 months for detailed engineering and design, 18 to 30 months for construction and installation, 6 to 12 months for equipment qualification, and 6 to 12 months for process validation. Programs that recognize they will need internal commercial manufacturing at approval must initiate the build decision at Phase II or early Phase III to have the facility ready at launch.

What is a hybrid manufacturing model?

A hybrid manufacturing model combines internal and external manufacturing capacity across different steps of the production process or different products in the portfolio. The most common configuration is internal drug substance manufacturing paired with outsourced sterile fill-finish, which preserves internal control over the proprietary upstream and downstream process while avoiding the capital investment required for aseptic filling infrastructure. A second common hybrid is platform-based: internal manufacturing for the dominant product class, with CDMO outsourcing for specialized modalities.

When should a biotech company transition from CDMO-dependent to internal manufacturing?

The right time to transition is when the commercial manufacturing business case supports the capital investment and when the organizational capability can be built in time to meet commercial supply requirements. This typically occurs as a product approaches Phase III, when demand projections are sufficiently mature to model the break-even analysis with reasonable accuracy. Companies that wait until post-approval to begin the build decision consistently underestimate the 3-to-5-year facility timeline and face supply gaps at launch or are forced to extend CDMO dependence beyond the economic optimum.

Articles

Navigating the build vs. buy decision in biomanufacturing

To pour concrete or to partner up? Here is the financial and strategic framework for navigating the build vs. buy decision in biomanufacturing.

Written byTrevor J Henderson

| 8 min read

Aerial photograph of a pharmaceutical GMP manufacturing facility under construction, with steel framing of the new building visible beside a completed existing facility.

The decision to build internal GMP manufacturing capacity is made years before the facility is needed, against demand projections that carry substantial uncertainty. Programs that make this commitment too early, before commercial proof-of-concept, bear unnecessary capital risk. Programs that make it too late face supply gaps at launch.

Flow (2026)

Listen with Speechify

0:00

8:00

Highlights in this article

Key takeaways
The financial anatomy of a GMP facility investment
At what point does building internal capacity become more economic than outsourcing?
Beyond cost: the strategic and organizational dimensions of the decision
How does the analysis change for specialized manufacturing modalities?
Hybrid models: when neither full build nor full outsource is the answer
What does the build vs. buy decision mean for long-term competitive positioning?

The decision to build internal GMP manufacturing capacity or outsource production to a contract manufacturer is one of the most capital-intensive choices a biopharmaceutical company makes. It is also one of the most consequential: a facility built for one molecule and one manufacturing paradigm is difficult to repurpose when the pipeline evolves. Getting the build vs. buy decision right requires a framework that accounts for financial, operational, regulatory, and strategic variables simultaneously.


Key takeaways
Building a commercial-scale GMP biologics manufacturing facility requires capital investment in the range of $200 million to over $400 million depending on scale and modality, plus the 3 to 5 years typically required for engineering, construction, qualification, and process validation before the first GMP batch can be produced. This timeline means the build decision must be made years before commercial supply is needed, against demand projections that carry substantial uncertainty.
The break-even analysis between building internal capacity and continued CDMO outsourcing is driven primarily by commercial batch frequency. At low batch frequency, the annualized capital and operating cost of an internal facility divided by the number of batches per year exceeds the CDMO per-batch price. At high commercial batch frequency, the fixed cost of internal manufacturing is amortized across enough batches that in-house production becomes the lower-cost option.
The build vs. buy decision is not made once. Most programs outsource Phase I and Phase II supply to CDMOs because the internal capital investment cannot be justified before clinical proof-of-concept. The decision is revisited at Phase III, when the commercial manufacturing business case first becomes realistic to model, and at commercial launch, when actual demand data replaces projections in the analysis.
Specialized manufacturing modalities, including viral vectors, autologous cell therapy, ADC conjugation, and mRNA, change the build vs. buy calculus because the specialized infrastructure, containment requirements, and regulatory track record required for commercial production are concentrated in a limited number of facilities globally. Building internal capacity for these modalities requires workforce development and operational experience that can take as long to build as the facility itself.
Hybrid manufacturing models, in which a company builds internal drug substance manufacturing capacity while outsourcing fill-finish, or builds internal capability for high-volume platform processes while outsourcing specialized modalities, preserve strategic control over the highest-value manufacturing steps while avoiding capital investment in lower-differentiated infrastructure.

For the full CDMO partnership context in which the build vs. buy decision sits, including CDMO selection, technology transfer, and quality agreement structure, see the related article on navigating GMP facilities and outsourcing.

The financial anatomy of a GMP facility investment

The capital cost of a GMP biologics manufacturing facility is driven by several interacting variables: the scale of the bioreactors required for the projected commercial demand, the modality-specific infrastructure requirements (containment suites for ADC conjugation, negative-pressure cleanrooms for viral vectors, cryogenic storage for cell therapy), the level of automation and digital infrastructure built in at commissioning, and the local construction cost environment at the selected site. Research on CDMO needs in the biopharmaceutical sector confirms that building a biologics manufacturing facility carries a capital cost up to USD 400 million, a figure that excludes the cost of the accompanying quality system infrastructure, personnel recruitment and training, and the process validation batches required before commercial release.

The timeline from the build decision to the first GMP batch is typically 3 to 5 years for a greenfield facility. This includes 12 to 18 months of detailed engineering and facility design, 18 to 30 months of construction and equipment installation, 6 to 12 months of equipment commissioning and qualification, and 6 to 12 months of process validation at commercial scale. Programs that recognize they will need internal commercial manufacturing capacity at approval must initiate the construction decision at Phase II or early Phase III, not at the time of the BLA filing.

The operating cost structure of an internal facility differs fundamentally from CDMO per-batch pricing. Internal manufacturing carries high fixed costs: facility maintenance, quality system operation, headcount for production, quality control, quality assurance, and regulatory functions, and the ongoing capital expenditure for equipment replacement and facility upgrades. These fixed costs are incurred whether or not the facility is running batches in a given period. The per-batch cost of internal manufacturing is therefore highly sensitive to facility utilization rate, declining sharply as batch frequency increases and rising steeply when the facility is underutilized.

At what point does building internal capacity become more economic than outsourcing?

The break-even point between internal manufacturing and CDMO outsourcing is specific to each program, each facility configuration, and each market projection. Capacity planning research examining batch and perfusion bioprocesses across multiple biopharmaceutical facilities confirmed that build-vs-buy decisions must be scheduled several years in advance before a drug's full market potential, likely dose range, and cell line productivity are fully known, and that incorrect capacity planning has produced high-profile company acquisitions on both sides of the under- and over-capacity failure modes.

A simplified framework for the break-even analysis compares the annualized total cost of ownership for an internal facility against the annual total cost of CDMO manufacturing at the projected batch frequency. The internal facility cost includes amortized capital, annual operating costs (utilities, maintenance, quality, regulatory, and staffing), and the opportunity cost of the capital deployed. The CDMO cost includes the per-batch manufacturing fee, the technology transfer cost amortized over the manufacturing program, and the cost of supply chain management and quality oversight.

At commercial launch batch frequencies of one to four batches per year, which are common for specialty biologics with moderate market size, the break-even analysis typically favors CDMO outsourcing because the high fixed cost of an internal facility cannot be amortized across enough batches to produce a lower per-batch cost than the CDMO price. At batch frequencies above six to eight batches per year for a standard biologic, the internal facility typically reaches cost parity with CDMO pricing, and above that frequency, internal manufacturing usually becomes the lower-cost option.

These break-even thresholds shift based on the cost of the specific CDMO being compared. A specialized CDMO for viral vector manufacturing commands substantially higher per-batch fees than a general mAb CDMO, which means the break-even batch frequency where internal viral vector manufacturing becomes cost-competitive is lower than for conventional biologics. Conversely, the capital cost of building a viral vector manufacturing facility is substantially higher than a standard mAb facility, which partially offsets this advantage.

Beyond cost: the strategic and organizational dimensions of the decision

The financial break-even analysis is necessary but not sufficient for the build vs. buy decision. Strategic and organizational factors often determine the outcome in cases where the financial analysis is not clearly decisive, and sometimes override it even when it is.

Strategic control is the most frequently cited non-financial argument for building internal manufacturing capacity. A company that manufactures internally has direct control over production scheduling, batch prioritization, process changes, and quality system decisions that affect the drug product the patient receives. When a late-stage clinical event or a post-approval pharmacovigilance signal requires a rapid manufacturing response, a company with internal manufacturing can implement changes on its own authority and timeline. A company dependent on a CDMO must negotiate that response through the CDMO's change control process and quality system, with timelines that are not entirely under the sponsor's control.

Organizational capability is the underappreciated constraint in the build decision. A commercial GMP manufacturing facility requires a staffed organization capable of running it: validated production operators, QC analysts with validated methods, QA professionals managing the quality system and regulatory compliance, engineers maintaining and qualifying the equipment, and a leadership structure capable of managing FDA and EMA inspections. Building this organization requires years of recruitment, training, and qualification, and the talent market for experienced GMP manufacturing professionals is tight. Programs that model the build decision purely as a capital and cost question without accounting for the organizational timeline to staff and qualify the facility consistently underestimate the total implementation timeline.

How does the analysis change for specialized manufacturing modalities?

The build vs. buy framework operates differently for product classes where commercial CDMO capacity is constrained, where the specialized infrastructure required for commercial manufacturing is not yet widely available, or where the regulatory track record required for commercial production is built over multiple years of operational experience. Each of these conditions applies to different degrees across the specialized manufacturing modalities.

For viral vector manufacturing, the global supply of GMP-qualified, commercially proven manufacturing suites is limited relative to the number of programs competing for commercial manufacturing slots. A gene therapy program that plans to outsource commercial manufacturing indefinitely must consider whether a CDMO with the required capacity and regulatory track record will be available at commercial scale, at commercial batch cost, within the required timeline. In this environment, the build vs. buy decision involves not only the financial analysis but a supply chain security analysis about whether the outsource option will be reliably available.

For autologous cell therapy, the build vs. buy decision is further complicated by the ex vivo manufacturing model, in which each batch is a single patient dose manufactured in response to a specific patient order. CDMO outsourcing for autologous manufacturing requires tight integration between the CDMO's scheduling system and the sponsor's patient order management and logistics infrastructure. Some sponsors have concluded that the logistical and quality control complexity of managing this integration through a CDMO exceeds the cost of building internal autologous manufacturing capability, even at patient volumes that the financial analysis would otherwise suggest as CDMO territory.

Hybrid models: when neither full build nor full outsource is the answer

Most commercial biopharmaceutical manufacturers operate some form of hybrid manufacturing model in which internal and external manufacturing capacity are combined across different manufacturing steps or different products in the portfolio. The most prevalent hybrid configuration pairs internal drug substance manufacturing with outsourced fill-finish: the company builds and operates the upstream and downstream drug substance manufacturing infrastructure, which is where the proprietary process knowledge and the most differentiated manufacturing capability reside, while outsourcing the sterile fill-finish step to a contract fill-finish organization that amortizes the capital cost of its aseptic filling equipment and cleanrooms across many clients.

Sterile fill-finish is the manufacturing step where the capital cost relative to value contributed is often hardest to justify for an internal build. Aseptic filling lines, lyophilizers, and the sterile cleanroom infrastructure they require represent investments of $50 million to over $200 million for commercial-scale operations, and the regulatory qualification and sterile operations expertise required to operate them at an inspection-ready standard is a substantial organizational overhead. The economics of shared fill-finish CDMO capacity are therefore favorable for many programs that operate internal drug substance manufacturing. The related article on sterile fill-finish in commercial bioproduction explores the fill-finish capacity landscape and the specific challenges of securing commercial-scale fill-finish slots in a constrained market.

A second common hybrid is modality-based: companies build and operate internal manufacturing for their platform product class, typically mAbs for large pharma, while outsourcing specialized modality manufacturing (viral vectors, ADCs, mRNA) to CDMO partners with the specific capabilities those modalities require. This hybrid preserves the efficiency of internal platform manufacturing while avoiding the capital investment and capability development required for modalities that represent a minority of the portfolio.

What does the build vs. buy decision mean for long-term competitive positioning?

The build vs. buy decision has implications for competitive positioning that extend beyond the manufacturing economics of the current product. Companies that build and operate internal GMP manufacturing develop organizational capabilities, process knowledge, and quality system infrastructure that are difficult to replicate quickly. These capabilities become competitive assets when the company faces manufacturing challenges that require rapid internal decision-making, or when manufacturing excellence is itself a differentiator in markets where supply reliability matters to payers and prescribers. Benchmarking research on biopharmaceutical process development and manufacturing costs notes that decision tools for build-vs-buy capacity sourcing require modeling not just costs and timelines but clinical success rates across the development pipeline, because the capital committed to a manufacturing facility must be justified by the expected value of the products it will manufacture across a portfolio, not just a single program.

The evolution of a company from development-stage to commercial organization is often marked by the build vs. buy decision. Virtual biotech companies that have relied on CDMOs through clinical development must decide at the commercial stage whether to remain asset-light and CDMO-dependent or to build the internal manufacturing infrastructure that characterizes an integrated biopharmaceutical company. This is as much an organizational strategy question as a financial one: the decision to build internal manufacturing is also a decision to become an organization that employs GMP manufacturing professionals, manages regulatory manufacturing compliance, and develops process excellence as a core organizational capability.

This article was produced under Drug Discovery News' AI Editorial Guidelines.

Frequently Asked Questions (FAQs)

How much does it cost to build a commercial GMP biologics manufacturing facility?
Capital cost estimates for commercial-scale GMP biologics manufacturing facilities range from approximately $200 million for a modestly sized drug substance facility to over $400 million for large-scale commercial mAb manufacturing infrastructure, and substantially more for specialized modalities requiring contained suites for cytotoxic handling or dedicated viral vector production areas. These figures cover construction and equipment but exclude quality system implementation, personnel hiring and training, and process validation costs that are typically additional.
What is the break-even batch frequency where internal manufacturing becomes more economic than a CDMO?
The break-even batch frequency depends on the specific facility configuration, CDMO pricing, and product volume, but as a directional benchmark, commercial biologic programs producing fewer than four to six batches per year typically find CDMO outsourcing more economical than internal manufacturing when the full fixed cost of an internal facility is accounted for. Above that threshold, internal manufacturing often becomes cost-competitive. For specialized modalities like viral vectors where CDMO per-batch fees are substantially higher than standard mAb CDMOs, the break-even frequency may be lower despite higher internal facility costs.
What is the timeline from a build decision to first commercial GMP batch?
For a greenfield GMP facility, the timeline from build decision to first commercial GMP batch is typically 3 to 5 years: 12 to 18 months for detailed engineering and design, 18 to 30 months for construction and installation, 6 to 12 months for equipment qualification, and 6 to 12 months for process validation. Programs that recognize they will need internal commercial manufacturing at approval must initiate the build decision at Phase II or early Phase III to have the facility ready at launch.
What is a hybrid manufacturing model?
A hybrid manufacturing model combines internal and external manufacturing capacity across different steps of the production process or different products in the portfolio. The most common configuration is internal drug substance manufacturing paired with outsourced sterile fill-finish, which preserves internal control over the proprietary upstream and downstream process while avoiding the capital investment required for aseptic filling infrastructure. A second common hybrid is platform-based: internal manufacturing for the dominant product class, with CDMO outsourcing for specialized modalities.
When should a biotech company transition from CDMO-dependent to internal manufacturing?
The right time to transition is when the commercial manufacturing business case supports the capital investment and when the organizational capability can be built in time to meet commercial supply requirements. This typically occurs as a product approaches Phase III, when demand projections are sufficiently mature to model the break-even analysis with reasonable accuracy. Companies that wait until post-approval to begin the build decision consistently underestimate the 3-to-5-year facility timeline and face supply gaps at launch or are forced to extend CDMO dependence beyond the economic optimum.

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Trevor J Henderson
Trevor Henderson is the Creative Services Director for the Laboratory Products Group at LabX Media Group. With over two decades of experience, he specializes in scientific and technical writing, editing, and content creation. His academic background includes training in human biology, physical anthropology, and community health. Since 2013, he has been developing content to engage and inform scientists and laboratorians.
View Full Profile